Ranjan Chrisanthar

Vitenskapelige publikasjoner

Lønning, Per Eystein; Berge, Elisabet Ognedal; Bjørnslett, Merete Pauline; Minsaas, Laura; Chrisanthar, Ranjan ; Vetti, Hildegunn Høberg; Dulary, Cécile; Busato, Florence; Bjørneklett, Silje; Eriksen, Christine; Kopperud, Reidun Kristin; Axcrona, Ulrika; Davidson, Ben; Bjørge, Line; Evans, D. Gareth; Howell, Anthony; Salvesen, Helga; Janszky, Imre; Hveem, Kristian; Romundstad, Pål Richard; Vatten, Lars Johan; Tost, Jörg; Dørum, Anne; Knappskog, Stian (2018). White blood cell BRCA1 promoter methylation status and ovarian cancer risk. Annals of Internal Medicine. Vol. 168.
https://doi.org/10.7326/M17-0101

Yndestad, Synnøve; Austreid, Eilin; Knappskog, Stian; Chrisanthar, Ranjan ; Lilleng, Peer Kåre; Lønning, Per Eystein; Eikesdal, Hans Petter (2017). High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. Breast Cancer Research and Treatment. Vol. 163.
https://doi.org/10.1007/s10549-017-4160-5

Knappskog, Stian; Berge, Elisabet Ognedal; Chrisanthar, Ranjan ; Geisler, Stephanie; Staalesen, Vidar; Leirvaag, Beryl; Yndestad, Synnøve; de Faveri, Elise Norheim; Karlsen, Bård Ove; Wedge, David C.; Akslen, Lars A.; Lilleng, Peer Kåre; Løkkevik, Erik; Lundgren, Steinar; Østenstad, Bjørn; Risberg, Terje; Mjaaland, Ingvil; Aas, Turid; Lønning, Per Eystein (2015). Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Molecular Oncology. Vol. 9.
https://doi.org/10.1016/j.molonc.2015.04.008

Knappskog, Stian; Chrisanthar, Ranjan ; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Leirvaag, Beryl; Miletic, Hrvoje; Lønning, Per Eystein (2012). Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. 12 s. Breast Cancer Research. Vol. 14.
https://doi.org/10.1186/bcr3147

Chrisanthar, Ranjan ; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Skjønsberg, Gudbrand; Aas, Turid; Schlichting, Ellen; Fjøsne, Hans Erikssønn; Nysted, Arne; Lillehaug, Johan R.; Lønning, Per Eystein (2011). Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. 10 s. PLOS ONE. Vol. 6.
https://doi.org/10.1371/journal.pone.0019249

Knappskog, Stian; Bjørnslett, Merete Pauline; Myklebust, Line Merethe; Huijts, Petra E.A.; Vreeswijk, Maaike P.; Edvardsen, Hege; Guo, Yongli; Zhang, Xuemei; Yang, Ming; Ylisaukko-oja, Sanna K.; Alhopuro, Pia; Arola, Johanna; Tollenaar, Rob A.E.M.; van Asperen, Christi J; Seynaeve, Caroline; Staalesen, Vidar; Chrisanthar, Ranjan ; Løkkevik, Erik; Salvesen, Helga Birgitte; Evans, D. Gareth; Newman, William G.; Lin, Dongxin; Aaltonen, Lauri; Børresen-Dale, Anne-Lise; Tell, Grethe S; Stoltenberg, Camilla; Romundstad, Pål Richard; Hveem, Kristian; Lillehaug, Johan R.; Vatten, Lars Johan; Devilee, Peter; Dørum, Anne; Lønning, Per Eystein (2011). The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. Cancer Cell. Vol. 19.
https://doi.org/10.1016/j.ccr.2010.12.019

Chrisanthar, Ranjan ; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Berge, Elisabet Ognedal; Risberg, Terje; Mjaaland, Ingvil; Mæhle, Lovise Olaug; Engebretsen, Lars Fredri; Lillehaug, Johan; Lønning, Per Eystein (2008). CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. 15 s. PLOS ONE. Vol. 3:e0003062.
https://doi.org/10.1371/journal.pone.0003062

Lønning, Per Eystein; Knappskog, Stian; Staalesen, Vidar; Chrisanthar, Ranjan ; Lillehaug, Johan (2007). Breast cancer prognostication and prediction in the postgenomic era. 14 s. Annals of Oncology. Vol. 18.
https://doi.org/10.1093/annonc/mdm013

Knappskog, Stian; Chrisanthar, Ranjan ; Staalesen, Vidar; Borresen-Dale, AL; Børresen-Dale, Anne-Lise; Gram, Inger Torhild; Lillehaug, Johan Richard; Lonning, PE; Lønning, Per Eystein (2007). Mutations and polymorphisms of the p21B transcript in breast cancer. 3 s. International Journal of Cancer. Vol. 121.
https://doi.org/10.1002/ijc.22777

Stålesen, Vidar; Staalesen, Vidar; Knappskog, Stian; Chrisanthar, Ranjan ; Nordgard, Silje H; Nordgard, Silje H.; Løkkevik, Erik; Anker, Gun; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjåland, Ingvil; Mjaaland, Ingvil; Gram, Inger Torhild; Kristensen, Vessela N; Børresen-Dale, Anne-Lise; Lillehaug, Johan Richard; Lønning, Per Eystein (2006). The novel p21 polymorphism p21(G251A) is associated with locally advanced breast cancer. Clinical Cancer Research. Vol. 12.

Forskningsrapporter

Chrisanthar, Ranjan (2009). Resistance to chemotherapy in breast cancer : potential role of p21B, p27 and the p53 apoptotic pathway. ISBN: 978-82-308-0745-3. Universitetet i Bergen.
http://hdl.handle.net/1956/3444

Formidling

Chrisanthar, Ranjan (2009). 1. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicates a functional pathway associated with resistance to epirubicin in primary breast cancer. Forskerskolen i klinisk medisin. Forskerskolen i klinisk medisin.

Chrisanthar, Ranjan (2008). Genforandringer som årsak til kjemoresistans ved primær brystkreft.

Chrisanthar, Ranjan (2008). CHEK2 mutations affecting kinase activity together with mutations in TP53 indicates a functional pathway associated with resistance to epirubicin in primary breast cancer. 9th Bergen Conference on Cancer Research 2008.

Chrisanthar, Ranjan (2008). Betydningen av mutasjoner i CHEK2 genet i tillegg til TP53 mutasjoner for resistens mot epirubicin. Onkologisk Forum, Bergen, November 20-21, 2008.

Lønning, Per Eystein; Chrisanthar, Ranjan ; Staalesen, Vidar; Knappskog, Stian; Lillehaug, Johan (2007). Adjuvant treatment: the contribution of expression microarrays. Breast Cancer Research. Vol. 9.
https://doi.org/10.1186/bcr1812

Chrisanthar, Ranjan ; Knappskog, Stian; Staalesen, Vidar; Lillehaug, Johan; Lønning, Per Eystein (2007). P21/waf1 mutation and drug resistance to paclitaxel in locally advanced breast cancer. International Journal of Cancer. Vol. 120.
https://doi.org/10.1002/ijc.22595

Staalesen, Vidar; Knappskog, Stian; Chrisanthar, Ranjan ; Geisler, Stephanie; baumbusch, lars; Løkkevik, Erik; Østenstad, Bjørn; Geisler, Jurgen; Børresen-Dale, Anne-Lise; Lillehaug, Johan; Lønning, Per Eystein (2007). The MDM2 SNP309 G/T promoter polymorphism is associated with chemoresistance in primary breast cancers harbouring mutations in the TP53 gene. AACR annual meeting. AACR.

Chrisanthar, Ranjan (2006). Genforandringer som årsak til kjemoresistans ved primær brystkreft.
http://www.helse-bergen.no/forskning/genforandring